You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1929 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Carfilzomib (Triplet Therapy) - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
carfilzomib,
dexamethasone,
lenalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2024
Cancer facts
May 2014
Guidelines and Advice
Status: Current
ID: 7-A-2022-1-17v3
Version: 3
Oct 2023
Guidelines and Advice
Status: Current
ID: GL-C50-05
Jan 2009
Guidelines and Advice
Status: Current
ID: GL 4-18
Version: N/A
Sep 2020
 
Guidelines and Advice
Status: Archived
ID: GL-7-A-2016-3
Apr 2017

Pages